MedTrace Logo

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

NCT00952588 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.

Conditions

Interventions

DRUG

AZD1152

1200 mg, iv, 7 day infusion

DRUG

LDAC

20 mg, sc, bd, 10 days

Sponsors & Collaborators

Principal Investigators

  • Paul Stockman · AstraZeneca

  • Hagop Kantarjian · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States
  • Australia
  • France
  • Germany
  • Italy
  • Japan
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00952588 on ClinicalTrials.gov